Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Abivax (ABVX) EBITDA Margin: 2022-2025

Historic EBITDA Margin for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to 720.61%.

  • Abivax's EBITDA Margin rose 11385287.00% to 720.61% in Q2 2025 from the same period last year, while for Jun 2025 it was 1,071.93%, marking a year-over-year decrease of 67448.00%. This contributed to the annual value of -1,389.54% for FY2024, which is 136692.00% up from last year.
  • Latest data reveals that Abivax reported EBITDA Margin of 720.61% as of Q2 2025, which was down 28.45% from 1,007.20% recorded in Q1 2025.
  • In the past 5 years, Abivax's EBITDA Margin ranged from a high of 1,007.20% in Q1 2025 and a low of -113,132.26% during Q2 2024.
  • Its 3-year average for EBITDA Margin is -18,403.93%, with a median of 360.52% in 2023.
  • In the last 5 years, Abivax's EBITDA Margin plummeted by 40bps in 2024 and then spiked by 11,385,287bps in 2025.
  • Over the past 4 years, Abivax's EBITDA Margin (Quarterly) stood at -1,408.70% in 2022, then soared by 140,912bps to 0.42% in 2023, then plummeted by 40bps to 0.02% in 2024, then soared by 11,385,287bps to 720.61% in 2025.
  • Its EBITDA Margin was 720.61% in Q2 2025, compared to 1,007.20% in Q1 2025 and 0.02% in Q4 2024.